BioNTech in conflict with regulator over new COVID vaccine nod: WAS newspaper
The reason for this was that the approval "should go through the same regulatory process as ordinary flu vaccines", which would allow the new COVID-19 vaccine to be delivered in three months, WAS cited Sahin as saying.
Berlin: The launch of German drugmaker BioNTech's vaccine adapted to the Omicron coronavirus variant may be delayed due to a disagreement with the regulator over the approval process, the Welt Am Sonntag (WAS) newspaper reported on Saturday.The regulator should still decide by the end of June whether or not to approve the new vaccine but BioNTech Chief Executive Ugur Sahin does not plan to...
Berlin: The launch of German drugmaker BioNTech's vaccine adapted to the Omicron coronavirus variant may be delayed due to a disagreement with the regulator over the approval process, the Welt Am Sonntag (WAS) newspaper reported on Saturday.
Read also: Pfizer-BioNTech COVID vaccines effective, safe for children aged 6 months to 4 years: USFDA staff
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd